SGA / Partial D2·Psychiatry - Oral Antipsychotics

Brexpiprazole

Schizophrenia

Authority requiredPBSSGARexulti4 mg tablet+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

4 mg/day

Half-life

91 h

Akathisia

LOWER THAN ARI

Caution: Renal Adj.

DOSE RED.

Cautions

Avoid / Cautions

Known hypersensitivity. Pregnancy Category C.

Where it stands

Rapid Summary

Overview

Next-generation partial dopamine agonist (structurally similar to Aripiprazole). Designed to provide the same metabolic safety as Aripiprazole but with vastly reduced rates of agonizing akathisia.

Clinical Focus

Exceptionally long half-life. Takes nearly 2 weeks to reach steady state.

Bottom Line

Brexpiprazole is a next-generation partial dopamine agonist with less akathisia than aripiprazole, but has limited clinical differentiation and is more expensive.

Formulation & Access

Brand Names

Rexulti

Oral Routes

Tablets (0.25, 0.5, 1, 2, 3, 4 mg).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Schizophrenia.

Off-Label

OFF

Adjunctive treatment of Major Depressive Disorder.

Clinical Place

Often the direct switch target for a patient who responds beautifully to Aripiprazole but cannot tolerate the severe restlessness (akathisia).

Quick reference

Class & Role

SGA / Partial D2 — Next-generation partial dopamine agonist (structurally similar to Aripiprazole).

Route / Formulation

Tablets (0.25, 0.5, 1, 2, 3, 4 mg). (Rexulti)

Usual Dose & Max

Start PO 1 mg OD. Titrate up over 1-2 weeks. Target 2-4 mg OD. Max 4 mg/day (Schizophrenia) or 3 mg/day (MDD adjunct).

Key Indication Doses

Schizophrenia: Start PO 1 mg OD. Titrate up over 1-2 weeks. Target 2-4 mg OD. MDD Adjunct: Start PO 0.5-1 mg OD. Max 3 mg/day. Renal / Hepatic Impairment: Max 3 mg/day if eGFR < 60 or in moderate/severe hepatic impairment.

Best Uses

Brexpiprazole is a next-generation partial dopamine agonist with less akathisia than aripiprazole, but has limited clinical differentiation and is more expensive.

Key Risks

Neurological: Akathisia (9%, compared to ~25% for Aripiprazole), headache, tremor. Metabolic: Weight gain (slightly more than Aripiprazole, but much less than Olanzapine/Quetiapine). Endocrine: Does not raise prolactin.

Key Interactions

Strong CYP2D6 inhibitors (Fluoxetine, Paroxetine) or CYP3A4 inhibitors (Clarithromycin) require the Brexpiprazole dose to be halved. If on BOTH, dose must be quartered.

Monitoring

Baseline BSL, Lipids, and Weight. Monitor for akathisia (pacing, rocking, inability to sit still), though risk is mitigated.

Clinical Pearl

Because Brexpiprazole binds to the D2 receptor but activates it less strongly than Aripiprazole, it is less 'stimulating'. It sits perfectly in the goldilocks zone between the heavy sedation of Quetiapine and the intense activation of Aripiprazole.

Access

Authority requiredRexulti4 mg tablet

Brand: Rexulti
PBS status: Authority required
Formulation: Tablets (0.25, 0.5, 1, 2, 3, 4 mg).

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.

SGA / Partial D2·Psychiatry - Oral Antipsychotics

Brexpiprazole

Schizophrenia

Authority requiredPBSSGARexulti4 mg tablet+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

4 mg/day

Half-life

91 h

Akathisia

LOWER THAN ARI

Caution: Renal Adj.

DOSE RED.

Cautions

Avoid / Cautions

Known hypersensitivity. Pregnancy Category C.

Where it stands

Rapid Summary

Overview

Next-generation partial dopamine agonist (structurally similar to Aripiprazole). Designed to provide the same metabolic safety as Aripiprazole but with vastly reduced rates of agonizing akathisia.

Clinical Focus

Exceptionally long half-life. Takes nearly 2 weeks to reach steady state.

Bottom Line

Brexpiprazole is a next-generation partial dopamine agonist with less akathisia than aripiprazole, but has limited clinical differentiation and is more expensive.

Formulation & Access

Brand Names

Rexulti

Oral Routes

Tablets (0.25, 0.5, 1, 2, 3, 4 mg).

Prescribing & PBS

Authority Required (PBS).

Indications & Use

Primary

PBSTGA

Schizophrenia.

Off-Label

OFF

Adjunctive treatment of Major Depressive Disorder.

Clinical Place

Often the direct switch target for a patient who responds beautifully to Aripiprazole but cannot tolerate the severe restlessness (akathisia).

Quick reference

Class & Role

SGA / Partial D2 — Next-generation partial dopamine agonist (structurally similar to Aripiprazole).

Route / Formulation

Tablets (0.25, 0.5, 1, 2, 3, 4 mg). (Rexulti)

Usual Dose & Max

Start PO 1 mg OD. Titrate up over 1-2 weeks. Target 2-4 mg OD. Max 4 mg/day (Schizophrenia) or 3 mg/day (MDD adjunct).

Key Indication Doses

Best Uses

Brexpiprazole is a next-generation partial dopamine agonist with less akathisia than aripiprazole, but has limited clinical differentiation and is more expensive.

Key Risks

Key Interactions

Strong CYP2D6 inhibitors (Fluoxetine, Paroxetine) or CYP3A4 inhibitors (Clarithromycin) require the Brexpiprazole dose to be halved. If on BOTH, dose must be quartered.

Monitoring

Baseline BSL, Lipids, and Weight. Monitor for akathisia (pacing, rocking, inability to sit still), though risk is mitigated.

Clinical Pearl

Access

Authority requiredRexulti4 mg tablet

Brand: Rexulti
PBS status: Authority required
Formulation: Tablets (0.25, 0.5, 1, 2, 3, 4 mg).

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.